Home / Business and Economy / Formosa Pharma & Rxilient Ink Eye Drug Deal
Formosa Pharma & Rxilient Ink Eye Drug Deal
4 Dec, 2025
Summary
- Formosa Pharmaceuticals and Rxilient Medical inked a deal for eye drug Byqlovi.
- The drug, APP13007, treats inflammation and pain after ocular surgery.
- APP13007, approved by the FDA in 2024, offers twice-daily dosing.
Formosa Pharmaceuticals and Rxilient Medical have signed an exclusive licensing agreement, paving the way for the commercialization of Byqlovi, clobetasol propionate ophthalmic suspension, 0.05% (APP13007), across several Association of Southeast Asian Nations (ASEAN) markets.
This strategic partnership grants Rxilient Medical the rights to market APP13007 in Thailand, Singapore, the Philippines, and Indonesia. The patented medicine is designed to treat inflammation and pain experienced by patients following ocular surgery. The deal includes upfront payments and sales and regulatory milestones.
APP13007, which received US FDA approval in 2024, utilizes Formosa's advanced particle nanotech (APNT) formulation. This innovative approach allows for a convenient twice-daily dosing schedule over 14 days, providing sustained and rapid relief for patients recovering from eye surgery.
